Maternal serum Lamin A is a potential biomarker that can predict adverse pregnancy outcomes

• Published in: EBioMedicine Vol. 77; p. 103932
• Main Authors: Chen, Lizhu, Xiu, Yun, Wu, Qijun, Wang, Yu, Zhang, Yixin, Xue, Jia, Wang, Qinbo, Yuan, Zhengwei
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2022; Elsevier
• Subjects: Biomarkers - blood; Case-Control Studies; Congenital heart defects; Female; Heart Defects, Congenital; Humans; Lamin Type A - blood; LMNA; Neural Tube Defects; Pre-Eclampsia; Preeclampsia; Pregnancy; Pregnancy Outcome; Prospective Studies; Serum biomarker; Serum biomarker; Neural tube defects; Preeclampsia; Congenital heart defects; LMNA
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2022.103932

Maternal serum Lamin A (LMNA) was reported to have potential diagnostic value in the prenatal diagnosis of congenital heart disease (CHD). In this study, we aimed to further assess the prognostic value of maternal serum LMNA in predicting adverse pregnancy outcomes. A prospective screening study was performed on singleton pregnancies at 15–18 weeks of gestation. After a routine test for alpha fetoprotein (AFP), chorionic gonadotropin (hCG), and unconjugated estriol (uE3), serum LMNA levels were measured. Serum LMNA levels were then converted into multiples of the median (MoM). The median MoM values for adverse pregnancy outcomes were compared with those in normal pregnancies. For diseases with differential LMNA expression in the prospective study, another case-control cohort was recruited. The diagnostic value of LMNA in these diseases was further evaluated. Between January 1, 2017 and June 30, 2018, a total of 2906 singleton pregnancies were recruited. Of the 2,906 cases, 2711 had data available for analysis. Congenital structural abnormalities, chromosomal abnormalities, and obstetric complications were observed in 152 (5·6%), 15 (0·6%), and 278 (10·3%) patients, respectively. LMNA was downregulated in pregnancies with fetal CHD, fetal neural tube defects (NTD), and preeclampsia (PE). The case-control study cohort included 256 CHD, 60 NTD, 67 PE, and 400 normal pregnancies. The areas under the curve for the prenatal diagnoses of CHD, NTD, and PE were 0·875, 0·871, and 0·816, respectively. Maternal serum LMNA was found to be a potential biomarker for the prenatal diagnosis of fetal CHD, NTD, and PE. National Key Research and Development Program, National Natural Science Foundation of China, LiaoNing Revitalization Talents Program, National Natural Science Foundation of Liaoning, and 345 Talent Project of Shengjing Hospital.